Maxygen News

Maxygen, Inc. , a biotechnology company, today announced that its Board of Directors has approved a new stock repurchase program under which the company may purchase up to $10.0 million of its common stock through December 31, 2012.

Maxygen, Inc. today announced that it has been advised by the Biomedical Advanced Research and Development Authority that Maxygen's proposal for the development of its MAXY-G34 product candidate as a potential medical countermeasure for Acute Radiation Syndrome will not be considered for a contract award.

This report provides information on the therapeutic development for Neutropenia, complete with latest updates, and special features on late-stage and discontinued projects.

Maxygen, Inc. , a biotechnology company, today announced that the United States Patent and Trademark Office has issued a Right of Appeal Notice in the inter partes reexamination proceeding for Amgen's U.S. Pat.

Maxygen, Inc. , a biotechnology company, today announced that its Board of Directors has approved an increase to the company's current stock repurchase program from $10.0 million to $20.0 million. The repurchase program expires on December 31, 2011.